ONLY DUPIXENT IS INDICATED FOR OCS-DEPENDENT ASTHMA PATIENTS1

DUPIXENT inhibits IL-4 and IL-13 signaling, two of the key drivers of type 2 inflammation1,2,a

aThe mechanism of action of dupilumab has not been definitively established.1

Be in the know about your patients’ OCS use

2 or more steroid bursts in the past year may be a sign of uncontrolled asthma3

  • Up to 84% of adult asthma patients present with type 2 inflammation4,5
KNOW WHY

Repeated OCS use
may be a sign of
uncontrolled asthma

  • Approximately half a million asthma patients were treated with 2 or more bursts this past year6
  • Patients who experience 2 or more OCS bursts within a year may have uncontrolled asthma3

Uncontrolled asthma
may be driven in part by
type 2 inflammation3

  • Up to 84% of adult asthma patients present with type 2 inflammation4,5
Know the full picture

Dig deeper to uncover the history of patients’ OCS use

78%of adult patients who see an asthma specialist received an OCS prescription from someone other than their specialist7
1
BURST 1

Received OCS prescription at urgent care facility for intensified asthma symptoms

2
BURST 2

Received OCS prescription at ED visit for a severe asthma exacerbation

3
BURST 3

Received OCS burst from primary care provider

4
BURST 4

Once again received OCS prescription at urgent care facility for a severe asthma exacerbation

RISK OF ADVERSE EFFECTS FROM OCS
IS CUMULATIVE
AND BECOMES SIGNIFICANT AFTER 4 LIFETIME BURSTS8

Hypothetical OCS regimen.

kNOW the RISKS

Repeated OCS use can lead to short- and long-term side effects3

Potential
SHORT-TERM
side effects3

Increased risk
of fracture

Sleep
disturbance

Increased risk
of infection

Increased risk of
thromboembolism

Potential
LONG-TERM
side effects3

Obesity

Cataracts

Diabetes

Anxiety/
Depression

Hypertension

Osteoporosis

Adrenal
suppression

See how DUPIXENT can break the cycle of repeated OCS use1,9

Know DUPIXENT

Are you seeking to reduce or eliminate OCS use and improve asthma control for your patients?

VENTURE (WEEK 24)

Only DUPIXENT reduced or eliminated steroids while simultaneously improving asthma control1,9

86%
of patients reduced or eliminated their OCS dose9,b
59%
reduction was observed in severe exacerbations1,9,c
220 mL
improvement in lung function in asthma patients who required daily OCS9,d

No biomarker requirement, ITT population: Reduced or eliminated OCS dose and reduced severe exacerbation rates and improved lung function (secondary endpoints) at Week 241,9,e-g

  • 70% significant mean reduction in OCS dose (median 100%) from baseline at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint)1
  • Effects on lung function and on oral steroid and exacerbation reduction were similar irrespective of baseline blood eosinophil levels. Subjects with baseline blood eosinophil levels up to 1500 cells/μL were included1

b At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) in VENTURE.9

c At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63]) in VENTURE.1

d At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference: 220 mL [95% CI: 90 mL, 340 mL]) in VENTURE.9

e ITT population was unrestricted by minimum baseline eosinophils or other type 2 biomarkers (eg, FeNO or IgE).9

f The baseline mean OCS dose was 12 mg in the placebo group and 11 mg in the group receiving DUPIXENT.1

g VENTURE: Asthma exacerbation was defined as a temporary increase in OCS dose for at least 3 days. TRAVERSE: Severe asthma exacerbations were defined as requiring systemic corticosteroids for ≥3 days, hospitalization, or ED visit.1,10

DUPIXENT has long-term data in measures of asthma control

TRAVERSE OLE
89%

reduction in
OCS dose at
Week 9611,g

AND
79%

reduction in
exacerbations through
Week 9610,11,g,i

AND
220mL

improvement
in lung function from
PSBL by Week 9611,j

  • 79% of patients from VENTURE eliminated their OCS dose10,11

A gradual increase in the number of patients eliminating their OCS dose was observed from 53.3% at Week 0 (n=48) to 59.6% at Week 48 (n=34) to 78.9% at Week 96 (n=15) in the DUPIXENT/DUPIXENT group (TRAVERSE OLE study, secondary endpoint).10,11,k

TRAVERSE OLE results are descriptive. Definitive conclusions cannot be made.

Data were not multiplicity controlled and there are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.

hFrom PSBL for patients who received DUPIXENT 300 mg Q2W + SOC in the parent study and continued on DUPIXENT during the open-label extension study (n=19).11

i Rate of unadjusted annualized exacerbations through Week 96 in the DUPIXENT/DUPIXENT group (n=90) was 0.39 from a mean of 1.90 exacerbations in the year prior to VENTURE.10,11

j 250 mL improvement in FEV1 at Week 96 of TRAVERSE from VENTURE baseline in the DUPIXENT/DUPIXENT group (n=28) vs 360 mL in the placebo/DUPIXENT group (n=32).11

k OCS reduction was at investigators’ discretion.11

ED, emergency department; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; GINA, Global Initiative for Asthma; ITT, intention-to-treat; LSM, least squares mean; OCS, oral corticosteroid; OLE, open-label extension; PSBL, parent study baseline; Q2W, once every 2 weeks; SOC, standard of care.

Explore the Safety data and study designs

VIEW SAFETY DATA SEE THE FULL STUDY DESIGNS

Dosage and Administration

See the multiple dosage and administration options for patients on DUPIXENT.

Explore ADMINISTRATION Options